Related Experiment Videos
Cimetidine does not increase alpha 1-acid glycoprotein serum concentrations
R C Parish1, V P Gotz, J L Mehta
1Department of Pharmacy Practice, College of Pharmacy, University of Georgia, Athens 30602.
British Journal of Clinical Pharmacology
|April 1, 1988
Summary
Cimetidine therapy did not significantly alter serum alpha 1-acid glycoprotein (AAG) concentrations in healthy volunteers. This suggests drug-AAG binding changes are unlikely to cause cimetidine drug interactions.
Area of Science:
- Pharmacology
- Biochemistry
Background:
- Alpha 1-acid glycoprotein (AAG) is a key plasma protein involved in drug binding.
- Cimetidine is a widely used medication known to affect drug metabolism and interactions.
Purpose of the Study:
- To investigate the effect of cimetidine administration on serum AAG concentrations.
- To determine if changes in AAG levels contribute to cimetidine-related drug interactions.
Main Methods:
- Six healthy male volunteers received cimetidine (300 mg every 6 h for 2 days).
- Serum AAG levels were measured at baseline, day 4, and day 6 of the study.
- Statistical analysis was performed to assess the impact of cimetidine and time of day on AAG concentrations.
Main Results:
- No significant differences in serum AAG concentrations were observed between baseline and post-cimetidine administration.
- Neither cimetidine treatment nor the time of day significantly affected serum AAG levels.
- No significant interaction was found between cimetidine treatment and time of day regarding AAG concentrations.
Conclusions:
- Cimetidine therapy does not appear to significantly alter serum AAG concentrations in healthy individuals.
- Altered drug-AAG binding due to cimetidine is unlikely to be a major mechanism for cimetidine drug interactions.